How to Use CRISPR to Accelerate Cancer Therapies

[Genscript] Webinar CJS nov 2 2018 How to Use CRISPR

The Use of qPCR to Validate Epigenetic Enrichment of Pathogen DNA from Complex Samples and Human DNA from Stool
  • Subscribe to Watch this Premium Webinar

    Get more information from Genscript and get instant access.
  • ​​All emails include an unsubscribe link. You may opt-out at any time. See our Privacy Policy & Terms & Conditions
  • This field is for validation purposes and should be left unchanged.

Tutorial Presented By

Contact us

GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a global leading biotech company that provides life sciences services and products to scientists over 100 countries worldwide. During our tenure we have built the best-in-class capacity and capability for biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.

Read more about the company


Theo Roth

Tutorial Video Abstract

Join Theo Roth as he describes his lab’s novel CRISPR-Cas9 genome-targeting system that does not require viral vectors to modify T cell genomes, but instead focuses on HDR. This allows rapid and efficient insertion of large DNA sequences at specific sites in the genomes of primary human T cells, and permits individual or multiplexed modification of endogenous genes. Importantly, avoiding the use of viral vectors will result in accelerated research and clinical applications, reduce experimental cost, and improve safety.

In this webinar, you will learn:

  •   The advantages of using HDR versus recombinant viral vectors when modifying T cell genomes
  •   How long double-stranded and single-stranded DNA can serve as a non-viral HDR template
  •   A novel method that allows for the insertion of large DNA sequences (>1Kb) without a virus!

Current efforts at reprogramming T cells for therapeutic purposes rely on using recombinant viral vectors. Unfortunately, viral vectors do not target transgenes to specific genomic sites. Moreover, the manufacturing and testing of effective viral vectors is often a lengthy and expensive process, which slows research progress and clinical use. However, recent studies have shown that re-engineering T cells in a specific and efficient manner is possible using homology-directed repair (HDR).

T lymphocyte
Share via
Copy link